Interpretation of Expert consensus on diagnosis and treatment of choroideremia (2024)
10.3760/cma.j.cn511434-20240611-00228
- VernacularTitle:《无脉络膜症临床诊疗中国专家共识（2024年）》解读
- Author:
Xiaoxu HAN
1
;
Ruifang SUI
Author Information
1. 中国医学科学院 北京协和医学院 北京协和医院眼科，北京 100730
- Keywords:
Choroideremia;
CHM gene variants;
Inherited ocular diseases;
Interpretation of expert consensus
- From:
Chinese Journal of Ocular Fundus Diseases
2024;40(7):495-499
- CountryChina
- Language:Chinese
-
Abstract:
Choroideremia (CHM) is a rare inherited eye disease that leads to blindness. It is caused by pathogenic variants in the CHM gene and exhibits X-linked recessive inheritance. Affected males present with progressively worsening night blindness, visual field loss, and decreased central vision, which can cause blindness in middle age. Although female carriers typically exhibit mild symptoms, it is essential to understand their clinical features for early diagnosis of patients as well as genetic counseling of family members. Currently, the recognition and diagnosis rates of CHM among ophthalmologists in various regions and levels of hospitals in China still need to be improved. A standardized clinical pathway is needed to meet the diagnostic and treatment needs of patients. Led by the the Chinese Hereditary Ocular Disease Diagnosis and the Treatment Group and the Chinese Hereditary Ocular Disease Alliance, based on existing evidence both domestically and internationally, the Expert consensus on diagnosis and treatment of choroideremia (2024) has been compiled, systematically and comprehensively elaborating on the standardized clinical pathways for CHM. Interpreting the key points of this consensus will help highlight its core points and ideas, enhancing the standardization and effectiveness of the diagnosis and treatment of CHM by ophthalmologists from all levels of hospitals.
